|Articles|March 1, 2016

Chinese CRO Adopts Medidata CTMS

R&G provides a full range of clinical trial services for both domestic and global partners.

R&G Pharma Studies, a Beijing, China-based CRO, has broadened its adoption of Medidata's Clinical Cloud, becoming the first Chinese customer to use Medidata CTMS.^® R&G provides a full range of clinical trial services-including regulatory affairs, clinical monitoring, data management capabilities, biostatistics, pharmacoeconomics, site management organization (SMO) services, and staffing and outsourcing-supporting studies on both a global and domestic scale.

Read the full release.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Chinese CRO Adopts Medidata CTMS

Related Content

Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research

Where Capability Gaps Hide When Scientific Intent Doesn't Translate Into Operations

ACT Brief: Product Development Assumptions, Portfolio-Level Recruitment Infrastructure, and Risk-Based Quality Integration

From Study-by-Study to Portfolio Recruitment: Q&A with Gaynor Anders, Trialbee

Why Execution Strategy Begins at the Business Decision, Not Study Startup

Trending on Applied Clinical Trials Online

From Study-by-Study to Portfolio Recruitment: Q&A with Gaynor Anders, Trialbee

ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN

Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research

ACT Brief: Sponsor Accountability in Outsourcing, Biomarker Strategy in Precision Oncology, and Novel Sciatica Therapy

Precision Oncology Trials Need to Reflect the Complexity of Cancer Biology